Anti-tim-3 antigen antibody or antibody derivative, and use thereof
US-2024391997-A1 · Nov 28, 2024 · US
US9963505B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9963505-B2 |
| Application number | US-201615094211-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 8, 2016 |
| Priority date | Sep 9, 2010 |
| Publication date | May 8, 2018 |
| Grant date | May 8, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FRβ.
Opening claim text (preview).
What is claimed is: 1. A method of treating a patient having an inflammatory disorder, said method comprising administering to said patient an amount of an isolated human monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds human folate receptor beta (FRβ) effective to reduce the number of FRβ positive macrophages and FRβ positive monocytes in said patient, wherein the antibody or fragment comprises a heavy chain variable region (V H ) complementarity determining region (CDR) 1 comprising the amino acid sequence set forth in SEQ ID NO:1; a V H CDR2 comprising the amino acid sequence set forth in SEQ ID NO:2; a V H CDR3 comprising the amino acid sequence set forth in SEQ ID NO:3; a light chain variable region (V L ) CDR1 comprising the amino acid sequence set forth in SEQ ID NO:4; a V L CDR2 comprising the amino acid sequence set forth in SEQ ID NO:5; and a V L CDR3 comprising the amino acid sequence set forth in SEQ ID NO:6; or wherein the antibody or fragment comprises a V H CDR1 comprising the amino acid sequence set forth in SEQ ID NO:1; a V H CDR2 comprising the amino acid sequence set forth in SEQ ID NO:2; a V H CDR3 comprising the amino acid sequence set forth in SEQ ID NO:3; a V L CDR1 comprising the amino acid sequence set forth in SEQ ID NO:14; a V L CDR2 comprising the amino acid sequence set forth in SEQ ID NO:15; and a V L CDR3 comprising the amino acid sequence set forth in SEQ ID NO:16.
Antineoplastic agents · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title
from primates, e.g. man · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.